Skip to main content
Springer logoLink to Springer
. 2021 Jul 30;81(12):1451. doi: 10.1007/s40265-021-01577-z

Correction to: Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis

Tamara Pérez-Jeldres 1,2, Manuel Alvarez-Lobos 1,2, Jesús Rivera-Nieves 3,4,
PMCID: PMC8496653  PMID: 34328627

Correction to: Drugs (2021) 81:985–1002 10.1007/s40265-021-01528-8

Please note that the drug cenerimod has been misspelled twice in this article as cerenimod.

Section 3.5.1 Cenerimod, second paragraph on page 994. The fourth sentence, which currently reads

“At week 11, 30% in the vehicle group died, whereas all cerenimod-treated mice survived.”

Should read:

“At week 11, 30% in the vehicle group died, whereas all cenerimod-treated mice survived.”

Section 4.2 Cardiovascular Events, first paragraph on page 944. The eighth sentence, which currently reads

“Conversely, up-titration is not required for compounds with long half-lives (fingolimod, cerenimod) due to the less pronounced first-dose-related negative chronotropic effects, presumably due to “built-in up-titration” [4, 110].”

Should read:

“Conversely, up-titration is not required for compounds with long half-lives (fingolimod, cenerimod) due to the less pronounced first-dose-related negative chronotropic effects, presumably due to “built-in up-titration” [4, 110].”


Articles from Drugs are provided here courtesy of Springer

RESOURCES